search

Active clinical trials for "Arthritis, Psoriatic"

Results 1-10 of 469

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque...

Plaque PsoriasisPsoriatic Arthritis

The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)

Recruiting26 enrollment criteria

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Psoriatic Arthritis

This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.

Recruiting8 enrollment criteria

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable...

Autoimmune DiseaseCrohn Disease12 more

This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Recruiting25 enrollment criteria

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic...

ArthritisPsoriatic

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

Recruiting10 enrollment criteria

Diet Interventions in Psoriatic Arthritis

Psoriatic Arthritis

The purpose of this study is to learn whether changing diet impacts psoriatic arthritis (PsA).

Recruiting18 enrollment criteria

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants...

Psoriatic Arthritis

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Recruiting13 enrollment criteria

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Psoriatic Arthritis

The trial is a double-blinded randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.

Recruiting12 enrollment criteria

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Psoriatic Arthritis

The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis. Approximately 195 eligible participants will take VTX958 Dose A, VTX958 Dose B, or matching placebo (no active drug) for 16 weeks and then move on to a 36 week Long Term Extension (LTE). The study will include 16 weeks of treatment, 36 weeks of LTE, and a 30-day follow-up period.

Recruiting10 enrollment criteria

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis...

ArthritisJuvenile

The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).

Recruiting11 enrollment criteria

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile...

Behçet's DiseaseJuvenile Psoriatic Arthritis

The primary objective of this study is to evaluate the long-term safety of apremilast in participants 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.

Recruiting12 enrollment criteria
12...47

Need Help? Contact our team!


We'll reach out to this number within 24 hrs